%0 Journal Article
%T The Pharmacological Options in the Treatment of Eating Disorders
%A W. Milano
%A M. De Rosa
%A L. Milano
%A A. Riccio
%A B. Sanseverino
%A A. Capasso
%J ISRN Pharmacology
%D 2013
%R 10.1155/2013/352865
%X The eating disorders (DCA) are complex systemic diseases with high social impact, which tend to become chronic with significant medical and psychiatric comorbidities. The literature data showed that there is good evidence to suggest the use of SSRIs, particularly at high doses of fluoxetine, in the treatment of BN reducing both the crisis of binge that the phenomena compensates and reducing the episodes of binge in patients with BED in the short term. Also, the topiramate (an AED) showed a good effectiveness in reducing the frequency and magnitude of episodes of binge with body weight reduction, both in the BN that is in the therapy of BED. To date, modest data support the use of low doses of second-generation antipsychotics in an attempt to reduce the creation of polarized weight and body shapes, the obsessive component, and anxiety in patients with AN. Data in the literature on long-term drug treatment of eating disorders are still very modest. It is essential to remember that the pharmacotherapy has, however, a remarkable efficacy in treating psychiatric disorders that occur in comorbidity with eating disorders, such as mood disorders, anxiety, insomnia, and obsessive-compulsive personality disorders and behavior. 1. Introduction The eating the disorders (ED) include several pathological conditions such as anorexia nervosa (AN), bulimia nervosa (BN), the binge eating disorder (BED), and eating disorders not otherwise specified [1]. DCA are important diseases with high social impact, affecting mainly the younger members of the population with a clinical course characterized by frequent exacerbations or relapses tending to become chronic, significant sequelae medical and psychiatric comorbidities that make these diseases among the most debilitating and fatal within psychiatric [2]. The lifetime prevalence of these diseases is currently estimated at 0.6% for AN, 1% for BN, and about 3% for BED [3]. The treatment of the DCA is substantially multidimensional and includes psychotherapy, nutritional rehabilitation, and drug treatment, both to control the core symptoms of DCA and to treat frequent psychiatric comorbidities, extremely frequent in this group of pathologies [4]. Basically all the drugs introduced in the clinic were tested in an attempt to treat the clinical manifestations of eating disorders, although often with contradictory results. Among other issues, it is important to note that, with the exception of fluoxetine for the treatment of bulimia nervosa (BN), nowadays, no drug has been approved by the national and international regulatory
%U http://www.hindawi.com/journals/isrn.pharmacology/2013/352865/